お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
599426

がんペプチドワクチンの世界市場の分析 (2020年)

Global Peptide Cancer Vaccine Market Research Report 2020

出版日: | 発行: QYResearch | ページ情報: 英文 167 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
がんペプチドワクチンの世界市場の分析 (2020年)
出版日: 2020年03月02日
発行: QYResearch
ページ情報: 英文 167 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のがんペプチドワクチンの市場について分析し、治療法・製品の概要や現在の治験状況、市場動向・平均価格の動向見通し (過去・今後6年間分)、地域別・症状別の詳細動向、製品開発動向 (パイプライン製品情報)、主要企業のプロファイル、今後の市場機会・課題などを調査しております。

第1章 がんペプチドワクチン市場の概要

  • がんペプチドワクチン:製品概要
  • がん治療におけるペプチドワクチン戦略
  • 世界のがんペプチドワクチン市場:用途別の内訳
    • がんペプチドワクチンの市場収益額シェア:用途別 (2025年)
    • 乳がん
    • 肺がん
    • 黒色腫
    • 前立腺がん
  • 世界のがんペプチドワクチン市場:地域別 (2020~2030年)
    • 市場規模・成長率の比較:地域別 (2020~2030年)
    • 米国市場:現状と展望 (2020~2030年)
    • 欧州市場:現状と展望 (2020~2030年)
    • 日本市場:現状と展望 (2020~2030年)
    • 中国市場:現状と展望 (2020~2030年)
    • 南米市場:現状と展望 (2020~2030年)
  • 世界のがんペプチドワクチンの市場規模 (2020~2030年)
  • 世界のがんペプチドワクチン・メーカー:本社所在地、創立年度、製品

第2章 がんワクチンと免疫療法

  • 治療用ワクチン
    • 自家がんワクチン
    • 同種がんワクチン
    • がんタンパクワクチン/がんペプチドワクチン
    • DNAワクチン
  • その他のアプローチ
  • 治療用がんワクチンの臨床的考察
    • 治験の初期/後期段階における検討
    • 治験の初期段階における検討
    • 治験の後期段階における検討

第3章 主要ながんに対する、ペプチドがんワクチンの薬効範囲の広さ

  • ペプチドと大腸がん
    • 大腸がん:概略
    • 大腸がん患者数:概略
    • 大腸がんにたいするがんペプチドワクチン治療:概略
  • ペプチドと肺がん
  • ペプチドと膵臓がん
  • ペプチドと乳がん
  • ペプチドと前立腺がん
  • ペプチドとその他のがん

第4章 がんペプチドワクチンのパイプライン製品

  • ITK-1
  • GRN-1201
  • TPIV200
  • TPIV110
  • UV1
  • galinpepimut-S
  • TARP 27-35
  • HER-Vaxx
  • Vx-001
  • VX-006
  • Vx-016
  • AE37
  • ISA101(HPV)
  • MyISA? (新抗原に基づく個別化免疫療法)
  • ISA203 (PRAME)
  • ISA204 (HBV)
  • OTSA101
  • GALINPEPIMUT-SとKEYTRUDA? (ペンブロリズマブ)
  • ACTolog?
  • DSP-7888投与エマルジョン:ベバシズマブとの併用
  • DSP-7888:骨髄異形成症候群 (MDS) 患者向け
  • DSP-7888:再発性・難治性の悪性神経膠腫の小児患者向け
  • DSP-7888投与エマルジョン:成人の進行黒色腫患者向け

第5章 世界のがんワクチンの消費量:地域別 (2013~2018年)

  • 世界のがんワクチン消費量:地域別 (2013~2018年)
  • 北米のがんワクチン消費量 (2013~2018年)
  • 欧州のがんワクチン消費量 (2013~2018年)
  • 中国のがんワクチン消費量 (2013~2018年)
  • 日本のがんワクチン消費量 (2013~2018年)

第6章 がんワクチンの市場規模の分析:主要企業別 (2013~2018年)

  • がんワクチンの販売量・市場シェア:メーカー別 (2013~2018年)
  • がんワクチンの市場収益額・市場シェア:メーカー別 (2013~2018年)
  • 主要企業の市場シェア
    • Merck
    • GSK
    • Dendreon

第7章 がんペプチドワクチンの主要メーカーの分析

  • Boston Biomedical
    • 会社概要
    • 商品情報
  • Ultimovacs
  • BrightPath Biotherapeutics
  • TapImmune
  • Immatics
  • Sellas
  • Imugene
  • VAXON Biotech
  • Generex Biotechnology
  • ISA Pharmaceuticals
  • OncoTherapy Science

第8章 がんペプチドワクチンの製造コスト分析

  • がんペプチドワクチン関連の研究開発 (R&D) 費用の分析
    • 治験フェーズ別 (相別) 費用
    • 資本化費用
  • 製造コストの構造比率
    • 原材料
    • 人件費
    • その他の費用の分析
  • がんペプチドワクチンの製造工程

第9章 産業連関構造、調達戦略、下流工程バイヤー

  • がんペプチドワクチンの創薬・治験動向の分析
  • 上流工程からの原材料調達
  • 下流工程部門のバイヤー

第10章 マーケティング戦略分析

  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネルの発展動向
  • 市場ポジショニング
    • 価格戦略
    • ブランド戦略

第11章 市場の影響の要因の分析

  • 関連産業の技術進歩
  • 消費者のニーズ/顧客の好みの変化
  • 経済的/政治的環境変化

第12章 世界のがんペプチドワクチン市場の予測 (2020~2030年)

  • 世界のがんペプチドワクチン市場:市場収益額の予測 (2020~2030年)
  • 市場収益額の予測:地域別 (2020~2030年)
  • 消費量の予測:地域別 (2020~2030年)
    • 米国市場
    • 欧州市場
    • 中国市場
    • 日本市場
    • 南米市場
  • がんペプチドワクチンの消費量の予測:用途別 (2020~2030年)

第13章 分析結果・結論

第14章 分析手法・情報源

図表

List of Tables and Figures

  • Table 1. Peptide Cancer Vaccine Market Size (M USD) Comparison by Regions (2020-2030) 8
  • Table 2. Global Players/Manufacturers Peptide Cancer Vaccine Headquarters and Established Date 12
  • Table 3. Global Manufacturers Peptide Cancer Vaccine Product 13
  • Table 4. Top 20 Countries Highest Incidence of Colorectal Cancer in 2016 20
  • Table 5. Top 20 Countries Highest Incidence of Lung Cancer in 2016 21
  • Table 6. Active Immunotherapies in Phase III Development 23
  • Table 7. Top 20 Countries Highest Incidence of Pancreatic Cancer in 2016 25
  • Table 8. Active Immunotherapies in Phase III Development 26
  • Table 9. Top 20 Countries Highest Incidence of Breast Cancer in 2016 27
  • Table 10. Active Immunotherapies in Phase III Development 29
  • Table 11. Information about World Cancer Statistics for the Most Common Cancers (excluding non-melanoma Skin Cancer) in 2016 32
  • Table 12. Active Immunotherapies in Phase III Development 33
  • Table 13. Global Cancer Vaccine Consumption (K Doses) Market by Regions (2013-2018) 53
  • Table 14. Global Cancer Vaccine Consumption Market Share by Regions (2013-2018) 53
  • Table 15. Table Global Cancer Vaccine Revenue (M USD) Market by Regions (2013-2018) 54
  • Table 16. Table Global Cancer Vaccine Revenue Market Share by Regions (2013-2018) 55
  • Table 17. Table Global Cancer Vaccine Sales (K Doses) of Key Manufacturers (2013-2018) 61
  • Table 18. Table Global Cancer Vaccine Sales Market Share by Manufacturers (2013-2018) 61
  • Table 19. Table Global Cancer Vaccine Revenue (M USD) by Manufacturers (2013-2018) 62
  • Table 20. Table Global Cancer Vaccine Revenue Share by Manufacturers (2013-2018) 62
  • Table 21. Merck Company Profile 64
  • Table 22. Cancer Vaccine Product Information of Merck 65
  • Table 23. Cancer Vaccine Sales (K Doses), Price (USD/Dose), Cost (USD/Dose), Gross (USD/Dose), Revenue (M USD) and Gross Margin of Merck 2013-2018 67
  • Table 24. GSK Company Profile 68
  • Table 25. Cancer Vaccine Product Information of GSK 69
  • Table 26. Cancer Vaccine Sales (K Doses), Price (USD/Dose), Cost (USD/Dose), Gross (USD/Dose), Revenue (M USD) and Gross Margin of GSK 2013-2018 70
  • Table 27. Dendreon Company Profile 71
  • Table 28. Cancer Vaccine Product Information of Dendreon 72
  • Table 29. Cancer Vaccine Sales (K Doses), Price (USD/Dose), Cost (USD/Dose), Gross (USD/Dose), Revenue (M USD) and Gross Margin of Dendreon 2013-2018 73
  • Table 30. Boston Biomedical Company Profile 75
  • Table 31. Ultimovacs Company Profile 76
  • Table 32. Peptide Cancer Vaccine Product Picture and Specifications of Ultimovacs 77
  • Table 33. BrightPath Biotherapeutics Company Profile 79
  • Table 34. TapImmune Company Profile 82
  • Table 35. Immatics Company Profile 85
  • Table 36. Sellas Company Profile 87
  • Table 37. Imugene Company Profile 88
  • Table 38. VAXON Biotech Company Profile 90
  • Table 39. Generex Biotechnology Company Profile 92
  • Table 40. ISA Pharmaceuticals Company Profile 94
  • Table 41. OncoTherapy Science Company Profile 96
  • Table 42. Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound 101
  • Table 43. Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound 102
  • Table 44. Average Price of Electricity to Ultimate Customers 2007-2018 109
  • Table 45. China Cost of Electricity 2017 (PER KWH) 112
  • Table 46. Major Buyers of Peptide Cancer Vaccine 118
  • Table 47. Global Peptide Cancer Vaccine Revenue (M USD) Forecast by Regions (2020-2025) 133
  • Table 48. Global Peptide Cancer Vaccine Revenue (M USD) Forecast by Regions (2025-2030) 134
  • Table 49. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Regions (2020-2025) 134
  • Table 50. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Regions (2025-2030) 134
  • Table 51. Global Peptide Cancer Vaccine Consumption (M USD) Forecast by Regions (2020-2025) 136
  • Table 52. Global Peptide Cancer Vaccine Consumption (M USD) Forecast by Regions (2025-2030) 136
  • Table 53. Global Peptide Cancer Vaccine Consumption Market Share Forecast by Regions (2020-2025) 136
  • Table 54. Global Peptide Cancer Vaccine Consumption Market Share Forecast by Regions (2025-2030) 137
  • Table 55. Global Peptide Cancer Vaccine Consumption (M USD) Forecast by Application (2020-2025) 142
  • Table 56. Global Peptide Cancer Vaccine Consumption (M USD) Forecast by Application (2025-2030) 143
  • Table 57. Global Peptide Cancer Vaccine Consumption Forecast by Application (2020-2025) 143
  • Table 58. Global Peptide Cancer Vaccine Consumption Forecast by Application (2025-2030) 143
  • Table 59. Research Programs/Design for This Report 146
  • Table 60. Key Data Information from Secondary Sources 149
  • Table 61. Key Data Information from Primary Sources 151
  • Figure 1. Product Picture of Peptide Cancer Vaccine 1
  • Figure 2. Global Peptide Cancer Vaccine Revenue Market Share by Applications in 2025 4
  • Figure 3. Breast Cancer Examples 5
  • Figure 4. Lung Cancer Examples 6
  • Figure 5. Melanoma Examples 7
  • Figure 6. Prostate Cancer Examples 7
  • Figure 7. USA Peptide Cancer Vaccine Revenue (M USD) and Growth Rate (2020-2030) 8
  • Figure 8. Europe Peptide Cancer Vaccine Revenue (M USD) and Growth Rate (2020-2030) 9
  • Figure 9. Japan Peptide Cancer Vaccine Revenue (M USD) and Growth Rate (2020-2030) 9
  • Figure 10. China Peptide Cancer Vaccine Revenue (M USD) and Growth Rate (2020-2030) 10
  • Figure 11. South America Peptide Cancer Vaccine Revenue (M USD) and Growth Rate (2020-2030) 11
  • Figure 12. Global Peptide Cancer Vaccine Revenue (M USD) Status and Outlook (2020-2030) 12
  • Figure 13. Percent of New Cases by Age Group: Lung Cancer 22
  • Figure 14. Percent of Deaths by Age Group: Lung Cancer 23
  • Figure 15. Percent of New Cases by Age Group: Prostate Cancer 30
  • Figure 16. Percent of Deaths by Age Group: Prostate Cancer 30
  • Figure 17. Estimated Prostate Cancer Incidence Worldwide in 2016 31
  • Figure 18. Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 34
  • Figure 19. Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 34
  • Figure 20. Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 35
  • Figure 21. Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 36
  • Figure 22. UV1 Technology 37
  • Figure 23. How HER-Vaxx is Tntended to Work 41
  • Figure 24. Molecular Modeling Study-MHC Class II Receptor 44
  • Figure 25. Li Suppression 44
  • Figure 26. Li-KEY Hybrid 45
  • Figure 27. Antitumor Activity of OTSA101 49
  • Figure 28. Peptide Cancer Vaccine Product Information of Sellas 49
  • Figure 29. Peptide Cancer Vaccine Product Information of Immatics 50
  • Figure 30. Peptide Cancer Vaccine Product Information of Boston Biomedical 51
  • Figure 31. Peptide Cancer Vaccine Product Information of Sumitomo Dainippon 51
  • Figure 32. Peptide Cancer Vaccine Product Information of Sumitomo Dainippon 51
  • Figure 33. Peptide Cancer Vaccine Product Information of Boston Biomedical 52
  • Figure 34. Global Cancer Vaccine Consumption Market Share by Regions (2013-2018) 54
  • Figure 35. Figure 2017 Global Cancer Vaccine Consumption Market Share by Regions 54
  • Figure 36. Figure Global Cancer Vaccine Revenue Market Share by Regions (2013-2018) 55
  • Figure 37. Figure 2017 Global Cancer Vaccine Revenue Market Share by Regions 56
  • Figure 38. Figure North America Cancer Vaccine Consumption (K Doses) and Growth Rate (2013-2018) 56
  • Figure 39. Figure North America Cancer Vaccine Revenue (M USD) and Growth Rate (2013-2018) 57
  • Figure 40. Figure Europe Cancer Vaccine Consumption (K Doses) and Growth Rate (2013-2018) 57
  • Figure 41. Figure Europe Cancer Vaccine Revenue (M USD) and Growth Rate (2013-2018) 58
  • Figure 42. Figure China Cancer Vaccine Consumption (K Doses) and Growth Rate (2013-2018) 58
  • Figure 43. Figure China Cancer Vaccine Revenue (M USD) and Growth Rate (2013-2018) 59
  • Figure 44. Figure Japan Cancer Vaccine Consumption (K Doses) and Growth Rate (2013-2018) 59
  • Figure 45. Figure Japan Cancer Vaccine Revenue (M USD) and Growth Rate (2013-2018) 60
  • Figure 46. Figure 2013 Cancer Vaccine Sales Market Share by Manufacturers 61
  • Figure 47. Figure 2017 Cancer Vaccine Sales Market Share by Manufacturers 62
  • Figure 48. Figure 2013 Global Cancer Vaccine Revenue Share by Manufacturers 63
  • Figure 49. Figure 2017 Global Cancer Vaccine Revenue Share by Manufacturers 63
  • Figure 50. Cancer Vaccine Sales (K Doses) and Growth Rate of Merck 2013-2018 67
  • Figure 51. Cancer Vaccine Revenue (M USD) and Global Market Share of Merck 2013-2018 68
  • Figure 52. Cancer Vaccine Sales (K Doses) and Growth Rate of GSK 2013-2018 70
  • Figure 53. Cancer Vaccine Revenue (M USD) and Global Market Share of GSK 2013-2018 71
  • Figure 54. Cancer Vaccine Sales (K Doses) and Growth Rate of Dendreon 2013-2018 73
  • Figure 55. Cancer Vaccine Revenue (M USD) and Global Market Share of Dendreon 2013-2018 74
  • Figure 56. Peptide Cancer Vaccine Product Information of Boston Biomedical 76
  • Figure 57. Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 80
  • Figure 58. Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 81
  • Figure 59. Peptide Cancer Vaccine Product Picture and Specifications of BrightPath Biotherapeutics 82
  • Figure 60. Peptide Cancer Vaccine Product Picture and Specifications of TapImmune 84
  • Figure 61. Peptide Cancer Vaccine Product Information of Immatics 86
  • Figure 62. Peptide Cancer Vaccine Product Information of Sellas 88
  • Figure 63. Peptide Cancer Vaccine Product Picture of Imugene 90
  • Figure 64. Peptide Cancer Vaccine Product Picture of VAXON Biotech 91
  • Figure 65. Peptide Cancer Vaccine Product Picture of Generex Biotechnology 93
  • Figure 66. Peptide Cancer Vaccine Product Picture of OncoTherapy Science 97
  • Figure 67. Typical Phases from Research to the Market for a Cancer Vaccine Candidate 100
  • Figure 68. Manufacturing Cost Structure of Peptide Cancer Vaccine 102
  • Figure 69. USA Labor Cost Analysis 2015-2018 103
  • Figure 70. Cost of Employing a Factory Worker 104
  • Figure 71. Europe Labor Cost Analysis 2015-2018 105
  • Figure 72. Germany Labor Cost Analysis 2015-2018 105
  • Figure 73. UK Labor Cost Analysis 2015-2018 106
  • Figure 74. France Labor Cost Analysis 2015-2018 106
  • Figure 75. Italy Labor Cost Analysis 2015-2018 106
  • Figure 76. Monthly Minimum Wages in Asia 2016 107
  • Figure 77. China Labor Costs 2015-2018 107
  • Figure 78. Japan Average Monthly Wages 2015-2018 108
  • Figure 79. Global Electricity Prices by Select Countries in 2017 (in U.S. Dollars per Kilowatt Hour) 109
  • Figure 80. Electricity Prices for Household Consumers in 2017 111
  • Figure 81. Anti-cancer Process 113
  • Figure 82. Manufacturing Process Analysis of Peptide Cancer Vaccine 114
  • Figure 83. Roadmap to the Development of Predictive Biomarkers for Active Immunotherapy 115
  • Figure 84. Peptide Cancer Vaccine Discovery and Development 116
  • Figure 85. Setting Pricing Policy 121
  • Figure 86. Global GDP Growth Rate for 2016 125
  • Figure 87. Real GDP Growth 2016-2020 annual Average 126
  • Figure 88. USA GDP 2008-2016 (Billion USD) 127
  • Figure 89. USA GDP Growth Rate Change 2015-2018 127
  • Figure 90. EU GDP 2008-2016 (Billion USD) 128
  • Figure 91. EU GDP Growth Rate Change 2015-2018 128
  • Figure 92. Germany GDP 2008-2016 (Billion USD) 129
  • Figure 93. Germany GDP Growth Rate 2015-2018 129
  • Figure 94. UK GDP 2008-2016 (Billion USD) 129
  • Figure 95. UK GDP Growth Rate 2015-2018 130
  • Figure 96. Italy GDP 2008-2016 (Billion USD) 130
  • Figure 97. Italy GDP Growth Rate 2015-2018 130
  • Figure 98. France GDP 2008-2016 (Billion USD) 131
  • Figure 99. France GDP Growth Rate 2015-2018 131
  • Figure 100. Japan GDP 2008-2016 (Billion USD) 131
  • Figure 101. Japan GDP Growth Rate 2015-2018 132
  • Figure 102. China GDP 2008-2016 (Billion USD) 132
  • Figure 103. China GDP Growth Rate 2015-2018 132
  • Figure 104. Global Peptide Cancer Vaccine Revenue (M USD) and Growth Rate Forecast (2020-2030) 133
  • Figure 105. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Regions (2020-2030) 135
  • Figure 106. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Regions in 2025 135
  • Figure 107. Global Peptide Cancer Vaccine Consumption Market Share Forecast by Regions (2020-2030) 137
  • Figure 108. Global Peptide Cancer Vaccine Consumption Market Share Forecast by Regions in 2025 138
  • Figure 109. USA Peptide Cancer Vaccine Consumption (M USD) and Growth Rate Forecast (2020-2030) 138
  • Figure 110. Europe Peptide Cancer Vaccine Consumption (M USD) and Growth Rate Forecast (2020-2030) 139
  • Figure 111. China Peptide Cancer Vaccine Consumption (M USD) and Growth Rate Forecast (2020-2030) 140
  • Figure 112. Japan Peptide Cancer Vaccine Consumption (M USD) and Growth Rate Forecast (2020-2030) 141
  • Figure 113. South America Peptide Cancer Vaccine Consumption (M USD) and Growth Rate Forecast (2020-2030) 142
  • Figure 114. Global Peptide Cancer Vaccine Consumption Forecast by Application (2020-2030) 144
  • Figure 115. Global Peptide Cancer Vaccine Consumption Forecast by Application in 2025 144
  • Figure 116. Bottom-up and Top-down Approaches for This Report 148
  • Figure 117. Data Triangulation 149
  • Figure 118. Key Executives Interviewed 151
目次

This report studies the Peptide Cancer Vaccine market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the Peptide Cancer Vaccine market by product type and applications/end industries.

The major players in global Peptide Cancer Vaccine market include

TapImmune

BrightPath Biotherapeutics

Ultimovacs

Sellas

Boston Biomedical

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

Immatics

Geographically, this report is segmented into several key Regions, with market size, market share and growth rate of Peptide Cancer Vaccine in these regions, from 2020 to 2030 (forecast), covering

USA

Europe

China

Japan

South America

RoW

On the basis on the end users/applications, this report covers

Breast Cancer

Lung Cancer

Melanoma

Prostate Cancer

Others

TABLE OF CONTENTS

1 PEPTIDE CANCER VACCINE MARKET OVERVIEW 1

  • 1.1 Peptide Cancer Vaccine Product Overview 1
  • 1.2 Peptide Vaccine Strategies in the Treatment of Cancer 1
  • 1.3 Global Peptide Cancer Vaccine Segment by Applications 4
    • 1.3.1 Global Peptide Cancer Vaccine Revenue Market Share by Applications in 2025 4
    • 1.3.2 Breast Cancer 4
    • 1.3.3 Lung Cancer 5
    • 1.3.4 Melanoma 6
    • 1.3.5 Prostate Cancer 7
  • 1.4 Global Peptide Cancer Vaccine Market by Regions (2020-2030) 8
    • 1.4.1 Global Peptide Cancer Vaccine Market Size and Growth Rate Comparison by Regions (2020-2030) 8
    • 1.4.2 USA Peptide Cancer Vaccine Status and Prospect (2020-2030) 8
    • 1.4.3 Europe Peptide Cancer Vaccine Status and Prospect (2020-2030) 9
    • 1.4.4 Japan Peptide Cancer Vaccine Status and Prospect (2020-2030) 9
    • 1.4.5 China Peptide Cancer Vaccine Status and Prospect (2020-2030) 10
    • 1.4.6 South America Peptide Cancer Vaccine Status and Prospect (2020-2030) 11
  • 1.5 Global Peptide Cancer Vaccine Market Size (2020-2030) 12
  • 1.6 Global Manufacturers Peptide Cancer Vaccine Headquarters, Established Date and Product 12

2 CANCER VACCINES AND IMMUNOTHERAPY 14

  • 2.1 Therapeutic Vaccines 14
    • 2.1.1 Autologous Cancer Vaccines 15
    • 2.1.2 Allogenic Cancer Vaccines 15
    • 2.1.3 Protein or Peptide Cancer Vaccines 16
    • 2.1.4 DNA Vaccines 16
  • 2.2 Other Approaches 16
  • 2.3 Clinical Considerations for Therapeutic Cancer Vaccines 17
    • 2.3.1 Considerations for both Early and Late Phase Clinical Trials 18
    • 2.3.2 Considerations for Early Phase Clinical Trials 18
    • 2.3.3 Considerations for Late Phase Clinical Trials 18

3 WIDE SPECTRUM ACTION OF PEPTIDE CANCER VACCINES AGAINST MAJOR CANCER 19

  • 3.1 Peptides & Colorectal Cancer 19
    • 3.1.1 Colorectal Cancer Introduction 19
    • 3.1.2 Introduction of the Number of Patients with Colorectal Cancer 19
    • 3.1.3 Peptide Cancer Vaccine Introduction about Colorectal Cancer 20
  • 3.2 Peptides & Lung Cancer 21
    • 3.2.1 Lung Cancer Introduction 21
    • 3.2.2 Introduction of the Number of Patients with Lung Cancer 21
    • 3.2.3 Peptide Cancer Vaccine Introduction about Lung Cancer 23
  • 3.3 Peptides & Pancreatic Cancer 24
    • 3.3.1 Pancreatic Cancer Introduction 24
    • 3.3.2 Introduction of the Number of Patients with Pancreatic Cancer 25
    • 3.3.3 Peptide Cancer Vaccine Introduction about Pancreatic Cancer 26
  • 3.4 Peptides & Breast Cancer 27
    • 3.4.1 Breast Cancer Introduction 27
    • 3.4.2 Introduction of the Number of Patients with Breast Cancer 27
    • 3.4.3 Peptide Cancer Vaccine Introduction about Breast Cancer 28
  • 3.5 Peptides & Prostate Cancer 29
    • 3.5.1 Prostate Cancer Introduction 29
    • 3.5.2 Introduction of the Number of Patients with Prostate Cancer 29
    • 3.5.3 Peptide Cancer Vaccine Introduction about Prostate Cancer 31
  • 3.6 Peptides & Other Cancer 32

4 GLOBAL PEPTIDE CANCER VACCINE BY PIPELINE 34

  • 4.1 ITK-1 34
  • 4.2 GRN-1201 35
  • 4.3 TPIV200 36
  • 4.4 TPIV110 36
  • 4.5 UV1 37
  • 4.6 galinpepimut-S 38
  • 4.7 TARP 27-35 39
  • 4.8 HER-Vaxx 39
  • 4.9 Vx-001 41
  • 4.10 Vx-006 42
  • 4.11 Vx-016 42
  • 4.12 AE37 43
  • 4.13 ISA101 (HPV) 45
  • 4.14 MyISA? (Personalized immunotherapy based on neoantigens) 46
  • 4.15 ISA203 (PRAME) 47
  • 4.16 ISA204 (HBV) 47
  • 4.17 OTSA101 48
  • 4.18 GALINPEPIMUT-S AND KEYTRUDA? (PEMBROLIZUMAB) 49
  • 4.19 ACTolog? 50
  • 4.20 DSP-7888 Dosing Emulsion plus Bevacizumab 51
  • 4.21 DSP-7888 in Patients with Myelodysplastic Syndrome (MDS) 51
  • 4.22 DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas 51
  • 4.23 DSP-7888 Dosing Emulsion in Adult Patients with Advanced Malignancies 52

5 GLOBAL CANCER VACCINE CONSUMPTION BY REGIONS (2013-2018) 53

  • 5.1 Global Cancer Vaccine Consumption by Regions (2013-2018) 53
  • 5.2 North America Cancer Vaccine Consumption (2013-2018) 56
  • 5.3 Europe Cancer Vaccine Consumption (2013-2018) 57
  • 5.4 China Cancer Vaccine Consumption (2013-2018) 58
  • 5.5 Japan Cancer Vaccine Consumption (2013-2018) 59

6 CANCER VACCINE MARKET SIZE ANALYSIS BY MAIN PLAYERS 2013-2018 61

  • 6.1 Global Cancer Vaccine Sales and Share by Manufacturers (2013-2018) 61
  • 6.2 Global Cancer Vaccine Revenue and Share by Manufacturers (2013-2018) 62
  • 6.3 Vaccine Market Size Analysis by Main Players 64
    • 6.3.1 Merck 64
    • 6.3.2 GSK 68
    • 6.3.3 Dendreon 71

7 ANALYSIS OF PEPTIDE CANCER VACCINE INDUSTRY KEY MANUFACTURERS 75

  • 7.1 Boston Biomedical 75
    • 7.1.1 Company Profile 75
    • 7.1.2 Product Information 76
  • 7.2 Ultimovacs 76
    • 7.2.1 Company Profile 76
    • 7.2.2 Product Information 77
  • 7.3 BrightPath Biotherapeutics 79
    • 7.3.1 Company Profile 79
    • 7.3.2 Product Information 80
  • 7.4 TapImmune 82
    • 7.4.1 Company Profile 82
    • 7.4.2 Product Information 84
  • 7.5 Immatics 85
    • 7.5.1 Company Profile 85
    • 7.5.2 Product Information 86
  • 7.6 Sellas 87
    • 7.6.1 Company Profile 87
    • 7.6.2 Product Information 88
  • 7.7 Imugene 88
    • 7.7.1 Company Profile 88
    • 7.7.2 Product Information 90
  • 7.8 VAXON Biotech 90
    • 7.8.1 Company Profile 90
    • 7.8.2 Product Information 91
  • 7.9 Generex Biotechnology 92
    • 7.9.1 Company Profile 92
    • 7.9.2 Product Information 93
  • 7.10 ISA Pharmaceuticals 94
    • 7.10.1 Company Profile 94
    • 7.10.2 Product Information 95
  • 7.11 OncoTherapy Science 96
    • 7.11.1 Company Profile 96
    • 7.11.2 Product Information 97

8 PEPTIDE CANCER VACCINE MANUFACTURING COST ANALYSIS 99

  • 8.1 Peptide Cancer Vaccine R&D Cost Analysis 99
    • 8.1.1 Clinical Phase Costs 100
    • 8.1.2 Capitalized Costs 101
  • 8.2 Proportion of Manufacturing Cost Structure 102
    • 8.2.1 Raw Materials 102
    • 8.2.2 Labor Cost 102
    • 8.2.3 Other Costs Analysis 109
  • 8.3 Manufacturing Process Analysis of Peptide Cancer Vaccine 113

9 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS 116

  • 9.1 Peptide Cancer Vaccine Peptide Cancer Vaccine Discovery and Development Analysis 116
  • 9.2 Upstream Raw Materials Sourcing 117
  • 9.3 Downstream Buyers 118

10 MARKETING STRATEGY ANALYSIS 119

  • 10.1 Marketing Channel 119
    • 10.1.1 Direct Marketing 119
    • 10.1.2 Indirect Marketing 119
    • 10.1.3 Marketing Channel Development Trend 119
  • 10.2 Market Positioning 120
    • 10.2.1 Pricing Strategy 120
    • 10.2.2 Brand Strategy 121

11 MARKET EFFECT FACTORS ANALYSIS 123

  • 11.1 Technology Progress in Related Industry 123
  • 11.2 Consumer Needs/Customer Preference Change 124
  • 11.3 Economic/Political Environmental Change 125

12 GLOBAL PEPTIDE CANCER VACCINE MARKET FORECAST (2020-2030) 133

  • 12.1 Global Peptide Cancer Vaccine Revenue Forecast (2020-2030) 133
  • 12.2 Global Peptide Cancer Vaccine Revenue Forecast by Regions (2020-2030) 133
  • 12.3 Global Peptide Cancer Vaccine Consumption Forecast by Regions (2020-2030) 136
    • 12.3.1 USA Peptide Cancer Vaccine Consumption Forecast (2020-2030) 138
    • 12.3.2 Europe Peptide Cancer Vaccine Consumption Forecast (2020-2030) 139
    • 12.3.3 China Peptide Cancer Vaccine Consumption Forecast (2020-2030) 140
    • 12.3.4 Japan Peptide Cancer Vaccine Consumption Forecast (2020-2030) 141
    • 12.3.5 South America Peptide Cancer Vaccine Consumption Forecast (2020-2030) 142
  • 12.4 Global Peptide Cancer Vaccine Consumption Forecast by Application (2020-2030) 142

13 RESEARCH FINDINGS AND CONCLUSION 145

14 METHODOLOGY AND DATA SOURCE 146

  • 14.1 Methodology/Research Approach 146
    • 14.1.1 Research Programs/Design 146
    • 14.1.2 Market Size Estimation 147
    • 14.1.3 Market Breakdown and Data Triangulation 148
  • 14.2 Data Source 149
    • 14.2.1 Secondary Sources 149
    • 14.2.2 Primary Sources 150
  • 14.3 Author List 152
  • 14.4 Disclaimer 152
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.